Skip to main content

Advertisement

SpringerLink
Log in

Pharmacotherapy in pediatric obesity: Current agents and future directions

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

Abstract

Childhood obesity is emerging as a major public health threat, with adverse implications on the health of individuals and long-term costs to society. Family-based lifestyle interventions with behavioral modification, diet and exercise form the mainstay of treatment. Pharmacologic treatment may be considered in selected subjects, especially in the presence of significant and severe comorbidities, when lifestyle intervention has failed to achieve weight reduction. Orlistat and sibutramine are FDA-approved for treatment of pediatric obesity; metformin may be considered in the presence of clinically significant insulin resistance. Evidence is lacking on the appropriate duration of medical therapy and optimal combination with lifestyle intervention. Lack of coverage of medications by insurance and high out-of-pocket costs may be limiting factors to some families. Adverse effects necessitate careful monitoring and may lead to discontinuation of medication. Pharmacologic agents with novel mechanisms of action offer hope of improved efficacy, tolerability and safety.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549–55.

    Article  PubMed  CAS  Google Scholar 

  2. Speiser PW, Rudolf MCJ, Anhalt H, et al. Consensus statement: childhood obesity. J Clin Endocrinol Metab. 2005;90:1871–87.

    Article  PubMed  CAS  Google Scholar 

  3. Baker JL, Olsen LW, Sorensen TIA. Childhood body mass index and the risk of coronary heart disease in adulhood. N Engl J Med. 2007;357:2329–37.

    Article  PubMed  CAS  Google Scholar 

  4. Bibbins-Domingo K, Coxson P, Pletcher MJ, et al. Adolescent overweight and future adult coronary heart disease. N Engl J Med. 2007;357:2371–9.

    Article  PubMed  CAS  Google Scholar 

  5. Barlow SE, the Expert Committee. Expert Committee recommendations regarding the prevention, assessment and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120(4):S164–92.

    Article  PubMed  Google Scholar 

  6. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003–2006. JAMA. 2008;299:2401–5.

    Article  PubMed  CAS  Google Scholar 

  7. Spear BA, Barlow SE, Ervin C, et al. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics. 2007;120:S254–88.

    Article  PubMed  Google Scholar 

  8. August GP, Caprio S, Fennoy I, et al. Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab. 2008;93:4576–99.

    Article  PubMed  CAS  Google Scholar 

  9. Sjostrom L, Rissanen A, Andersen T, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352:167–72.

    Article  PubMed  CAS  Google Scholar 

  10. Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160–7.

    Article  PubMed  CAS  Google Scholar 

  11. McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res. 2002;10:642–50.

    Article  PubMed  CAS  Google Scholar 

  12. Norgren S, Danielsson P, Jurold R, et al. Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatr. 2003;92:666–70.

    Article  PubMed  CAS  Google Scholar 

  13. McDuffie JR, Calis KA, Uwaifo GI, et al. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab. 2004;17:307–19.

    PubMed  CAS  Google Scholar 

  14. Ozkan B, Bereket A, Turan S, et al. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr. 2004;163:738–41.

    Article  PubMed  Google Scholar 

  15. Maahs D, de Serna DG, Kolotkin RL, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract. 2006;12:18–28.

    PubMed  Google Scholar 

  16. Chanoine J-P, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293:2873–83.

    Article  PubMed  CAS  Google Scholar 

  17. Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab. 2005;90:1460–5.

    Article  PubMed  CAS  Google Scholar 

  18. Garcia-Morales LM, Berber A, Macias-Lara CC, et al. Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controled, parallel-group trial. Clin Ther. 2006;28:770–82.

    Article  PubMed  CAS  Google Scholar 

  19. Berkowitz RI, Wadden TA, Tershakovec AM, et al. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA. 2003;289:1805–12.

    Article  PubMed  CAS  Google Scholar 

  20. Berkowitz RI, Fujioka K, Daniels SR, et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med. 2006;145:81–90.

    PubMed  CAS  Google Scholar 

  21. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107:E55.

    Article  PubMed  CAS  Google Scholar 

  22. Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50:1457–61.

    Article  PubMed  CAS  Google Scholar 

  23. Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006;91:2074–80.

    Article  PubMed  CAS  Google Scholar 

  24. Burgert TS, Duran EJ, Goldberg-Gell R, et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes. 2008;9:567–76.

    Article  PubMed  CAS  Google Scholar 

  25. Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin. J Pediatr. 2008;152:817–22.

    Article  PubMed  CAS  Google Scholar 

  26. Gibson WT, Farooqi IS, Moreau M, et al. Congenital leptin deficiency due to homozygosity for the delta-133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab. 2004;89:4821–6.

    Article  PubMed  CAS  Google Scholar 

  27. Carrel A, Moerchen V, Myers SE, et al. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr. 2004;145:744–9.

    Article  PubMed  CAS  Google Scholar 

  28. Lustig RH, Hinds PS, Ringwald-Smith K, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88:2586–92.

    Article  PubMed  CAS  Google Scholar 

  29. Despres J-P, Golay A, Sjostrom L, et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121–34.

    Article  PubMed  CAS  Google Scholar 

  30. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761–75.

    Article  PubMed  CAS  Google Scholar 

  31. Moreira FA, Grieb M, Lutz B. Central side effects of therapies based on CB1 cannabinoid receptor agonist and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab. 2009;23:133–44.

    Article  PubMed  CAS  Google Scholar 

  32. Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol. 2000;15(Suppl 1):S22–6.

    Article  PubMed  Google Scholar 

  33. Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007;68:1324–32.

    Article  PubMed  CAS  Google Scholar 

  34. Gadde KM, Franciscy DM, Wagner HR, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289:1820–5.

    Article  PubMed  CAS  Google Scholar 

  35. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–91.

    Article  PubMed  CAS  Google Scholar 

  36. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–100.

    Article  PubMed  CAS  Google Scholar 

  37. Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002;10:633–41.

    Article  PubMed  CAS  Google Scholar 

  38. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR versus placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049–56.

    Article  PubMed  CAS  Google Scholar 

  39. McGovern L, Johnson JN, Paulo R, et al. Treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. J Clin Endocrinol Metab. 2008;93:4600–5.

    Article  PubMed  CAS  Google Scholar 

  40. Oude Luttikhuis H, Baur L, Jansen H, et al. Interventions for treating obesity in children. Cochrane Database Syst Rev. 2009;1:CD001872.

    PubMed  Google Scholar 

  41. Uli N, Sundararajan S, Cuttler C. Treatment of childhood obesity. Curr Opin Endocrinol Diabetes Obes. 2008;15:37–47.

    PubMed  Google Scholar 

  42. Freemark M. Pharmacotherapy of childhood obesity: an evidence-based, conceptual approach. Diabetes Care. 2007;30:395–402.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

This work was supported in part by the Healthy Kids Healthy Weight program, Rainbow Babies & Children’s Hospital (NU).

Author information

Authors and Affiliations

  1. Division of Pediatric Endocrinology, UH Rainbow Babies & Children’s Hospital, Case Western Reserve University, 11100 Euclid Avenue, RB&C Suite 737, Cleveland, OH, 44106, USA

    Abigail B. Wald & Naveen K. Uli

Authors
  1. Abigail B. Wald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naveen K. Uli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naveen K. Uli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wald, A.B., Uli, N.K. Pharmacotherapy in pediatric obesity: Current agents and future directions. Rev Endocr Metab Disord 10, 205–214 (2009). https://doi.org/10.1007/s11154-009-9111-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11154-009-9111-y

Keywords

Search

Navigation